tradingkey.logo

XOMA Royalty Corp

XOMA
32.980USD
-0.240-0.72%
Close 10/31, 16:00ETQuotes delayed by 15 min
397.82MMarket Cap
LossP/E TTM

XOMA Royalty Corp

32.980
-0.240-0.72%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of XOMA Royalty Corp

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

XOMA Royalty Corp's Score

Industry at a Glance

Industry Ranking
29 / 79
Overall Ranking
178 / 4618
Industry
Media & Publishing

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
69.667
Target Price
+109.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

XOMA Royalty Corp Highlights

StrengthsRisks
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 372.66% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.49M.
Undervalued
The company’s latest PE is -23.39, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 8.23M shares, increasing 6.51% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 719.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 8.44, which is higher than the Media & Publishing industry's average of 7.29. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 13.13M, representing a year-over-year increase of 18.43%, while its net profit experienced a year-over-year increase of 45.99%.

Score

Industry at a Glance

Previous score
8.44
Change
0

Financials

6.67

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

7.83

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.71

XOMA Royalty Corp's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 7.13, which is lower than the Media & Publishing industry's average of 7.31. Its current P/E ratio is -23.39, which is -79.77% below the recent high of -4.73 and -61.65% above the recent low of -37.82.

Score

Industry at a Glance

Previous score
7.13
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 29/79
No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.00, which is higher than the Media & Publishing industry's average of 7.44. The average price target for XOMA Royalty Corp is 55.00, with a high of 104.00 and a low of 50.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts
Buy
Current Rating
69.667
Target Price
+111.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

17
Total
9
Median
11
Average
Company name
Ratings
Analysts
XOMA Royalty Corp
XOMA
4
Roku Inc
ROKU
33
Paramount Global
PARA
27
TKO Group Holdings Inc
TKO
23
Live Nation Entertainment Inc
LYV
23
Warner Music Group Corp
WMG
20
1
2
3
4

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 6.59, which is lower than the Media & Publishing industry's average of 6.81. Sideways: Currently, the stock price is trading between the resistance level at 37.52 and the support level at 30.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.66
Change
-0.07

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.737
Sell
RSI(14)
38.037
Neutral
STOCH(KDJ)(9,3,3)
23.434
Neutral
ATR(14)
1.691
Low Volatility
CCI(14)
-119.726
Sell
Williams %R
89.851
Oversold
TRIX(12,20)
-0.349
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
33.848
Sell
MA10
34.235
Sell
MA20
35.471
Sell
MA50
35.973
Sell
MA100
31.472
Buy
MA200
27.546
Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 5.00, which is lower than the Media & Publishing industry's average of 5.85. The latest institutional shareholding proportion is 68.05%, representing a quarter-over-quarter increase of 3.43%. The largest institutional shareholder is The Vanguard, holding a total of 638.81K shares, representing 5.28% of shares outstanding, with 36.18% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BVF Partners L.P.
2.59M
--
Morgan Stanley Investment Management Inc. (US)
1.52M
+38.09%
Fidelity Management & Research Company LLC
1.04M
+0.01%
The Vanguard Group, Inc.
Star Investors
638.81K
+39.15%
BlackRock Institutional Trust Company, N.A.
540.12K
+10.09%
Opaleye Management Inc.
255.09K
+0.81%
Geode Capital Management, L.L.C.
203.60K
+9.07%
Woodline Partners LP
180.23K
+6.93%
State Street Investment Management (US)
153.48K
+6.05%
Stonepine Capital Management, LLC
152.14K
+17.20%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 4.31, which is lower than the Media & Publishing industry's average of 4.93. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.31
Change
0
Beta vs S&P 500 index
1.11
VaR
+6.00%
240-Day Maximum Drawdown
+44.63%
240-Day Volatility
+59.09%

Return

Best Daily Return
60 days
+8.54%
120 days
+10.89%
5 years
+21.08%
Worst Daily Return
60 days
-7.83%
120 days
-8.33%
5 years
-18.47%
Sharpe Ratio
60 days
+2.22
120 days
+1.52
5 years
+0.25

Risk Assessment

Maximum Drawdown
240 days
+44.63%
3 years
+44.63%
5 years
+68.58%
Return-to-Drawdown Ratio
240 days
+0.23
3 years
+0.58
5 years
-0.05
Skewness
240 days
+0.48
3 years
+0.77
5 years
+0.69

Volatility

Realised Volatility
240 days
+59.09%
5 years
+67.74%
Standardised True Range
240 days
+4.32%
5 years
+4.41%
Downside Risk-Adjusted Return
120 days
+248.35%
240 days
+248.35%
Maximum Daily Upside Volatility
60 days
+36.00%
Maximum Daily Downside Volatility
60 days
+37.87%

Liquidity

Average Turnover Rate
60 days
+0.48%
120 days
+0.38%
5 years
--
Turnover Deviation
20 days
+81.14%
60 days
+80.61%
120 days
+40.74%

Peer Comparison

Media & Publishing
XOMA Royalty Corp
XOMA Royalty Corp
XOMA
7.03 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Fox Corp
Fox Corp
FOXA
8.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Fox Corp
Fox Corp
FOX
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
New York Times Co
New York Times Co
NYT
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Criteo SA
Criteo SA
CRTO
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Nexstar Media Group Inc
Nexstar Media Group Inc
NXST
8.02 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI